Valneva SE

VALNEVA Declaration of shares and voting rights: February 28, 2025

05 Mar 2025 12:00:00 By Nasdaq GlobeNewswire

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

03 Mar 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

28 Feb 2025 11:45:00 By Nasdaq GlobeNewswire

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

18 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Shareholding declaration Valneva SE - January 2025

06 Feb 2025 12:00:00 By Nasdaq GlobeNewswire

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®

05 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million 

30 Jan 2025 11:45:00 By Nasdaq GlobeNewswire

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

22 Jan 2025 11:45:00 By Nasdaq GlobeNewswire

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

20 Jan 2025 11:45:00 By Nasdaq GlobeNewswire

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

06 Jan 2025 11:45:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: December 31, 2024

03 Jan 2025 12:00:00 By Nasdaq GlobeNewswire

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

19 Dec 2024 02:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: November 30, 2024

05 Dec 2024 01:30:00 By Nasdaq GlobeNewswire

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

04 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

03 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

26 Nov 2024 11:45:00 By Nasdaq GlobeNewswire

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

13 Nov 2024 11:45:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

12 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

07 Nov 2024 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: October 31, 2024

06 Nov 2024 02:30:00 By Nasdaq GlobeNewswire